Sickle Cell Disease Treatment Market To Reach USD 6.9 Billion By 2032

Introduction

Global Sickle Cell Disease Treatment Market size is expected to be worth around US$ 6.9 Billion by 2032 from USD$ 2.2 Billion in 2023, growing at a CAGR of 14.10% during the forecast period from 2024 to 2032. In 2022, North America reaching a revenue total of US$ 703.0 Million.

Sickle cell disease (SCD) is an inherited genetic disorder that leads to the production of abnormal hemoglobin, causing red blood cells to become misshapen. These distorted cells obstruct blood flow, resulting in complications such as anemia, pain, swelling in the hands and feet, increased vulnerability to infections, and delayed growth in children. The condition occurs when a child inherits defective genes from both parents.

Diagnosis involves blood tests, genetic testing, and newborn screening programs. While there is no definitive cure, treatment options like blood transfusions and bone marrow transplants aim to alleviate symptoms and improve quality of life.

The global market for sickle cell disease treatments is expanding, driven by rising awareness, advancements in medical technology, and a growing need for effective therapies. Supportive government policies and collaborations between pharmaceutical companies and research organizations are further propelling market growth. However, the COVID-19 pandemic has disrupted healthcare services, affecting the timely diagnosis and treatment of individuals with hemoglobinopathies.

According to the World Health Organization (WHO), over 66% of the 120 million people affected by sickle cell disease globally reside in Africa. Approximately 1,000 children are born with the disease daily on the continent, making it the most prevalent genetically inherited condition in the region. Sadly, more than half of these children do not survive beyond the age of five, primarily due to severe anemia or infections.

Sickle cell disease significantly shortens the lifespan of red blood cells, resulting in a condition commonly referred to as sickle cell anemia. This disorder leads to reduced oxygen levels in the blood and blockages in blood vessels, causing severe pain in areas such as the back, chest, hands, and feet, along with heightened susceptibility to bacterial infections.

In 2019, the African region reported 38,403 deaths attributed to sickle cell disease, marking a 26% increase since 2000. Efforts to combat the disease are hindered by limited funding for preventive measures and treatment programs. Many public health facilities in the region lack the resources for early detection, prevention, and comprehensive disease management. Additionally, a shortage of trained healthcare professionals and inadequate primary healthcare infrastructure continue to impede effective management of this life-threatening condition.

Key Takeaways

• Market Size: Global Sickle Cell Disease Treatment Market size is expected to be worth around USD 6.9 Billion by 2032 from USD 2.2 Billion in 2023.
• Market Growth: The market growing at a CAGR of 14.10% during the forecast period from 2024 to 2032.
• Type Analysis: Hydroxyurea Segment Held Largest Share in Sickle Cell Disease Market.
• Application Analysis: Bone Marrow Transplant Dominate the Market in the Application Segment.
• Route Administration Analysis: The Oral Segment Dominates the Market Shares in the Route Administration Segment.
• End-Use Analysis: Hospital Segment Lead Due to Increasing Prevalence of Patients Visits.
• Regional Analysis: North America Dominate the Largest Shares in the Sickle Cell Disease Market.

Sickle Cell Disease Treatment Statistics

• Prevalence and Incidence
  • As of 2021, approximately 100,000 Americans are affected by sickle cell disease (SCD).
  • Globally, the population living with SCD increased from 5.46 million in 2000 to 7.74 million in 2021.
  • Each year, approximately 500,000 babies are born with SCD worldwide, with the majority in sub-Saharan Africa.
• Mortality Rates
  • In 2021, global deaths due to SCD were estimated at 376,000, exceeding cause-specific mortality estimates.
  • Among children under five, SCD caused approximately 81,100 deaths globally in 2021, ranking as the 12th leading cause of death in this age group.
  • In the United States, the crude mortality rate for SCD among Black individuals from 2010 to 2020 was 1.1 per 100,000, reflecting a slight decline compared to earlier decades.
• Life Expectancy and Treatment Outcomes
  • Historical data from the early 1990s shows the median life expectancy for individuals with SCD was 42 years for males and 48 years for females.
  • A reduced-intensity haploidentical bone marrow transplant trial demonstrated a 95% survival rate two years post-transplant, with 88% of participants experiencing no recurrence of the disease.
• Genetic Variants and Treatment Advances
  • Three main genotypes have been identified: severe sickle cell β-thalassaemia, sickle-haemoglobin C disease, and mild sickle cell β-thalassaemia.
  • Advances in gene therapy and other innovative treatments are offering new hope for effective disease management and improved outcomes.
• Geographical Variations
  • Since 2000, South Asia and sub-Saharan Africa have experienced the largest increases in SCD-related deaths, largely due to population growth.
  • SCD ranks among the top three causes of death in countries like Portugal, Jamaica, Libya, Oman, and San Marino as of 2021.

Sickle Cell Disease Treatment Analysis

• Bone Marrow Transplant (BMT): Bone marrow transplant (BMT) remains one of the few curative treatments for sickle cell disease (SCD). It involves replacing the patient’s defective marrow with healthy marrow from a donor. Historically, the best results have been achieved with fully matched sibling donors. Recent advancements, such as reduced-intensity haploidentical BMT, now allow for the use of half-matched donors, including parents or children. This innovation reduces complications, making the treatment accessible to a broader patient population, especially those without fully matched donors.
• Blood Transfusion: Blood transfusion is a cornerstone of supportive care in SCD management. Regular transfusions increase the proportion of healthy red blood cells, reducing risks such as stroke and acute chest syndrome. This intervention is particularly critical during severe anemia or pain crises, providing symptomatic relief and preventing further complications. Despite its benefits, blood transfusion is not curative and requires ongoing management to monitor and mitigate side effects like iron overload, commonly seen with repeated transfusions.
• Pharmacotherapy: Pharmacotherapy plays a vital role in symptom management for SCD. Medications like hydroxyurea enhance fetal hemoglobin production, reducing pain crises and acute chest syndrome. Newer drugs, such as voxelotor, improve hemoglobin’s oxygen affinity, decreasing sickling and hemolysis. While these treatments significantly improve the quality of life for patients, they do not offer a cure for the disease.
• Emerging Treatments: Gene therapy is a groundbreaking approach with the potential to cure SCD. This technique involves editing a patient’s hematopoietic stem cells to correct the genetic mutation responsible for the disease. Unlike traditional BMT, gene therapy eliminates the need for donor cells, avoiding risks such as graft-versus-host disease. Early-phase clinical trials, particularly using tools like CRISPR, have demonstrated promising results, offering durable treatment effects without the complexities associated with conventional transplants.

Emerging Trends

• Gene Therapy Advances: The approval of two gene therapies, CASGEVY and LYFGENIA, by the FDA marks a milestone in the treatment of sickle cell disease (SCD). These therapies leverage gene-editing technologies to modify patients’ blood stem cells, boosting fetal hemoglobin production. This shift towards potentially curative treatments offers hope for patients, particularly those suffering from recurrent vaso-occlusive crises.
• CRISPR Technology Implementation: The use of CRISPR gene-editing technology, exemplified in treatments like CASGEVY, has transformed the therapeutic landscape. By enabling precise genetic modifications, CRISPR enhances fetal hemoglobin production, preventing red blood cell sickling. These innovations promise to significantly reduce disease symptoms, improve quality of life, and extend life expectancy for patients with SCD.
• Increased Accessibility to Therapies: Efforts are being made to expand the reach of advanced gene therapies beyond specialized treatment centers. As these therapies become more integrated into clinical settings, there is a global push to make them accessible in diverse regions, ensuring broader availability of life-saving treatments.
• Comprehensive Care Models: The integration of advanced gene therapies with traditional SCD treatments is driving the development of comprehensive care models. These models aim to address both the genetic roots of the disease and its complications, providing holistic management of SCD for improved patient outcomes.
• Innovations in Treatment Delivery: New methods for delivering therapies are under investigation, including lipid nanoparticle technology, inspired by its success in mRNA COVID-19 vaccines. This approach has the potential to simplify the modification of blood stem cells in vivo, making treatments less invasive and more efficient.
• Focus on Pediatric Patients: Recognizing the importance of early intervention, there is a growing focus on pediatric patients with SCD. Tailored therapies are being developed to address the unique needs of children, offering the potential to alter the disease trajectory and improve long-term outcomes from an early age.

Use Cases

• Gene Therapy for Reducing Vaso-Occlusive Crises: Gene therapies such as Casgevy and Lyfgenia utilize CRISPR technology to edit patients’ stem cells, enhancing fetal hemoglobin production. This reduces the sickling of red blood cells, significantly decreasing the frequency of vaso-occlusive crises. These painful complications, common in sickle cell disease (SCD), are managed more effectively, improving patients’ quality of life and potentially increasing life expectancy.
• Hematopoietic Stem Cell Transplantation (HSCT): HSCT remains the only established curative option for SCD. It is particularly beneficial for patients with severe disease symptoms, such as frequent pain crises or acute chest syndrome. By replacing the patient’s defective marrow with healthy stem cells from a donor, ideally a matched sibling, HSCT restores normal blood cell production and mitigates disease manifestations.
• Preventive Measures for Stroke: Children with SCD are at heightened risk of stroke. Regular transcranial Doppler screenings, followed by interventions like blood transfusions or hydroxyurea therapy, help prevent strokes. These preventive measures enable early identification of high-risk children, reducing the occurrence of strokes and other neurological complications.
• Management of Chronic Pain and Acute Pain Crises: SCD often leads to chronic pain and acute pain crises. Treatment includes pain relief medications for immediate crises and comprehensive pain management plans for chronic conditions. These strategies enhance patients’ ability to perform daily activities, improving their overall comfort and quality of life.
• Prevention of Infections: Infections, particularly pneumonia, pose serious risks for individuals with SCD. Prophylactic measures, such as regular penicillin doses and routine vaccinations, are critical in preventing these life-threatening infections, forming a cornerstone of effective disease management.
• Innovative Treatment Delivery Approaches: Emerging methods for gene therapy delivery, such as lipid nanoparticle technology inspired by mRNA COVID-19 vaccines, offer a less invasive and more efficient approach. This technology simplifies the gene-editing process in patients’ stem cells, expanding the potential reach and applicability of advanced therapies.

Conclusion

Sickle cell disease (SCD) remains a significant global health challenge, particularly in Africa, where the prevalence and mortality rates are highest. Advances in treatments, including gene therapy, bone marrow transplants, and pharmacotherapy, offer promising solutions to manage and potentially cure the disease.

Despite these developments, access to effective treatments and resources remains uneven, exacerbated by limited healthcare infrastructure and funding in many regions. The global SCD treatment market is projected to grow significantly, driven by technological advancements, supportive policies, and increased awareness. Addressing accessibility challenges and prioritizing comprehensive care models will be critical to improving outcomes for patients worldwide.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF